Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAC-CAG regimen in newly diagnosed elderly acute myeloid leukemia
ChiCTR-OPC-17011225Phase 4Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- May 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of decitabine, cytarabine, aclarubicin and granulocyte colony-stimulating factor in acute myeloid leukemia (AML), sponsored by Tangdu Hospital. Primary endpoint: overall survival. Planned start May 2017; status: not yet recruiting.
02
Drugs
decitabinecytarabineaclarubicingranulocyte colony-stimulating factor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-OPC-17011225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17011225.